+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the safety, efficacy, and tolerability of sodium zirconium cyclosilicate SZC in children under 18 years old with hyperkalaemia, a condition involving high potassium levels. This phase 3, open-label study involves about 140 participants across roughly 46 sites in Europe, North America, and other locations. It starts with two age cohorts 6 to under 12 years and 12 to under 18 years, with potential expansion to younger cohorts based on data review by an independent monitoring committee. Treatment includes three phases the Correction Phase CP, Maintenance Phase MP, and Long-Term Maintenance Phase LTMP. Participants in CP receive SZC orally three times daily for up to 3 days until potassium levels normalize, with doses adjusted by body weight equivalent to adult doses of 5 g, 10 g, or 15 g. Those achieving normal potassium enter the MP, receiving once-daily SZC for 28 days with dose adjustments to maintain levels. Participants may then continue into the LTMP, following a similar dose regimen with monthly visits. Throughout the study, participants undergo blood tests, ECG monitoring, urine analyses, and safety assessments to track potassium levels, aldosterone, electrolytes, and kidney function. Researchers measure effectiveness by the ability to achieve and maintain normal potassium levels and monitor safety and tolerability in all phases. The study duration is about 28 weeks, including treatment and a safety follow-up one week after the last dose.

Age: 0Years - 18YearsAll GendersPhase 3
70 locations
L

Actively Recruiting

Researchers are studying the long-term safety and effectiveness of pembrolizumab MK-3475 in participants with advanced tumors or blood cancers who were part of previous pembrolizumab-based studies. This extension study includes participants currently receiving treatment or in follow-up from parent trials. It consists of three phases the First Course Phase, Survival Follow-up Phase, and Second Course Phase, depending on the participants status at the end of their previous study. Participants may receive pembrolizumab alone or combined with standard of care treatments, lenvatinib, or other study drugs like olaparib and MK-4280, delivered mainly by intravenous infusion or oral capsules. Dosing schedules vary, including pembrolizumab administered every 3 or 6 weeks for up to 35 or 17 doses depending on the phase. Some participants may take lenvatinib orally daily, timed with pembrolizumab infusions, while others may receive investigational combination therapies or standard care treatments according to their parent studys protocol. During the study, participants will have regular infusions or oral dosing and be monitored over several years for overall survival and other outcomes like progression-free survival and adverse events. Researchers will assess safety and efficacy for up to approximately 10 years, with detailed tracking of side effects and treatment discontinuations. Study visits and assessments will be conducted to evaluate organ function, disease status, and any treatment-related effects throughout the study duration.

Age: 18Years +All GendersPhase 3
782 locations
S

Actively Recruiting

Researchers are evaluating the impact of repetitive tactile stimulation compared to selective stimulation on the oxygen levels of preterm infants born before 32 weeks of gestation. This study uses a stepped-wedge cluster randomized controlled design, where entire centers switch from selective to repetitive stimulation over time. The goal is to see if repetitive stimulation improves oxygenation at 5 minutes after birth, based on prior evidence suggesting it may enhance respiratory effort and reduce the need for invasive support. Initially, participating centers will apply selective tactile stimulation by gently rubbing the infants back, chest, limbs, or soles only if breathing seems insufficient. Later, centers are randomly assigned to switch to repetitive stimulation, involving 10-second gentle rubbing followed by 10 seconds of rest, repeated for the first 5 minutes after birth or longer if needed. All other care procedures in the delivery room and neonatal intensive care unit follow standard guidelines throughout the study. During the trial, infants will be monitored closely with measures including oxygen saturation at 5 minutes after birth, heart rate, and respiratory support interventions such as CPAP and mechanical ventilation during the first minutes and week after birth. Additional assessments include cranial ultrasound and recording of interventions like surfactant administration. The study aims to understand how different tactile stimulation methods affect early oxygenation and respiratory outcomes in very preterm infants, with participation lasting through the first week after birth.

Age: 0 - 32WeeksAll GendersPhase Not Applicable
43 locations